(Q37974693)

26 August 2017

title

Pazopanib for the treatment of breast cancer (English)

1 reference

26 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

26 August 2017

author name string

Laleh Amiri-Kordestani

series ordinal

1 reference

26 August 2017

Antoinette R Tan

series ordinal

1 reference

26 August 2017

language of work or name

English

0 references

publication date

10 January 2012

1 reference

Expert Opinion on Investigational Drugs

26 August 2017

published in

1 reference

26 August 2017

1 reference

26 August 2017

1 reference

26 August 2017

page(s)

217-225

1 reference

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Induction of angiogenesis during the transition from hyperplasia to neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: Correlation with stage and rate of progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Pazopanib Reveals a Role for Tumor Cell B-Raf in the Prevention of HER2+ Breast Cancer Brain Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Coprescription of tamoxifen and medications that inhibit CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652304

10.1517/13543784.2012.652304

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference